
FILED



Plaintiff Thermolife International, LLC ("Plaintiff") hereby alleges for its Complaint against GNC Corporation; General Nutrition Centers, Inc.; and General Nutrition Corporation (collectively "Defendant"), on personal knowledge as to its own activities and on information and belief as to the activities of others, as follows:

I. THE PARTIES

- 1. Plaintiff is a limited liability company organized and existing under the laws of Arizona, with a place of business at 1811 Ocean Front Walk in Venice, California, 90291.
- 2. Plaintiff is the owner and assignee of United States Patent No. 8,202,908 ("the '908 patent") titled "D-Aspartic Acid Supplement," and Plaintiff licenses the '908 patent to several third-parties and is in negotiations to license the patents to numerous other parties.
- 3. On information and belief, GNC Corporation is a corporation incorporated under the laws of the State of Delaware with a principal place of business at 300 6th Avenue in Pittsburgh, Pennsylvania, 15222.
- 4. On information and belief, General Nutrition Centers, Inc. is a corporation incorporated under the laws of the State of Delaware with a principal place of business at 300 6th Avenue in Pittsburgh, Pennsylvania, 15222.
- 5. On information and belief, General Nutrition Corporation is a corporation incorporated under the laws of the Commonwealth of Pennsylvania with a principal place of business at 300 6th Avenue in Pittsburgh, Pennsylvania, 15222.
- 6. GNC Corporation; General Nutrition Centers, Inc.; and General Nutrition Corporation are affiliated companies that derive their revenues principally from product sales through "GNC"-branded company-owned and franchisee-owned stores and on the internet, primarily through www.gnc.com. They are collectively referred to herein as "Defendant."

27 | ///

28 || / / /

II. JURISDICTION AND VENUE

- 7. This is an action for patent infringement arising under the patent laws of the United States, Title 35 of the United States Code. Accordingly, this Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338, and 1367.
 - 8. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400.
- 9. This Court has personal jurisdiction over Defendant. By way of example and without limitation, Defendant, directly or through intermediaries (including distributors, retailers, and others), ships, distributes, offers for sale, sells, and advertises "Rebel"-branded dietary supplement products (hereinafter the "accused products") manufactured, marketed, and sold by Defendant in the United States, the State of California, and the Central District of California.
- 10. Defendant has purposefully and voluntarily placed these accused products into the stream of commerce with the expectation that they will be purchased in the Central District of California, and the products are actually purchased in the Central District of California.

III. THE DEFENDANT'S INFRINGING PRODUCT

- 11. The accused products purport to and do increase the levels of testosterone in adult male humans.
 - 12. The accused products are administered by oral ingestion.
- 13. The accused products contain a D-aspartic acid compound comprised from D-aspartic acid, D-Aspartate salts, or D-aspartate esters.
- 14. The accused products branded are intended to be taken by adult male humans and are taken primarily by adult male humans.
- 15. The accused products purport to contain and actually contain a D-aspartic acid compound which is, according to the products' instructions for use, to be administered and is administered in an amount and for a time sufficient to increase the levels of testosterone in end-users.

- 1 2
- 3 4
- 5 6
- 8

- 9
- 10 11
- 12
- 13

14

- 15 16
- 17
- 18

19 20

- 21
- 22 23
- 24 25
- 26
- 27
- 28

- 16. Defendant manufactures, markets, advertises, offers for sale, and sells the accused products.
- As part of its transaction of business in this jurisdiction, Defendant sells its 17. accused products to various distributors and retailers with places of business within the Central District of California.
- 18. The labels and advertisements for Defendant's product Rebel state, as relevant to this matter and without limitation, as follows:
 - a. The product contains "D-Aspartic Acid (DAA)"
 - b. It is to be taken by oral ingestion.
 - c. "anabolic compound featuring d-aspartic acid...."
 - d. "For maximum results consume 2 scoops daily"
 - e. The product includes 1 gram of DAA per scoop.

IV. THE DEFENDANT'S INFRINGEMENTS

19. Defendant has committed the tort of patent infringement within the State of California, and more particularly, within the Central District of California, by virtue of the fact that Defendant has shipped, distributed, offered for sale, sold, and advertised, and continues to ship, distribute, offer for sale, sell, and advertise the accused products in this District.

DIRECT INFRINGEMENTS Α.

20. Defendant's employees, agents, representatives and other sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities, have taken, used, and orally administered the accused products, which Defendant has formulated and distributed and sold to include a D-aspartic acid compound as defined in the '908 patent for the specific reason of increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the D-aspartic acid compound present in the product in an amount and for a time sufficient to increase the levels of testosterone.

11

13 14

16

19

21 22

24

23

25

26 27

28

- Defendant has encouraged and/or is aware of these persons' oral 21. administration of the accused products for these purposes, and these employees, agents, representatives and other persons sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities are acting under Defendant's direction and control when practicing the method disclosed in the '908 patent.
- Therefore, Defendant directly practices the method as set forth in the '908 22. patent and it is a direct infringer of the patent.

B. **INDIRECT INFRINGEMENTS**

- End-users of Defendant's accused products are also direct infringers of the '908 patent, because they have taken, used, and orally ingested the accused products which Defendant has formulated to include a D-aspartic acid compound as defined in the '908 patent for the specific reason of increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the a D-aspartic acid compound as defined in the '908 patent present in the products in an amount and for a time sufficient to increase their levels of testosterone.
- These end-users practice the method as set forth in the '908 patent and are 24. direct infringers of the patent.
- 25. Defendant's labels and advertising for the accused products explain the elements and essential elements of the method disclosed in the '908 patent to end-users and encourage, urge, and induce the accused products' end-users to purchase and orally ingest the products to practice that method, and end-users do practice that method.
- 26. Defendant has therefore specifically intended to cause these end-users to directly infringe the claimed methods of the patent, and have in fact urged them to do so.
- 27. The accused products are not suitable for non-infringing uses, and none of Defendant's labels or advertisements for the accused products disclose any uses for the

3 4

6 7

5

9 10

11

8

12 13 14

16 17

15

18 19

20 21

22 23

24

25 26

27

28

products nor for the D-aspartic acid compound as defined in the '908 patent in those products that do not infringe upon the method disclosed in the '908 patent.

- 28. The inclusion of the D-aspartic acid compound in the products is material to practicing the method disclosed in the '908 patent.
- 29. Defendant has knowledge that the accused products are especially adapted by end-users of the products for the practicing of the method disclosed in the '908 patent, and, indeed, Defendant encourages, urges, and induces the products' end-users to purchase and orally administer the accused products to practice that method, and has done so in the past.
- Defendant has intentionally and knowingly induced, encouraged, and 30. urged end-users of the accused products to purchase and orally administer the accused products for the purpose, without limitation, of increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the D-aspartic acid compound as defined in the '908 patent present in the products in an amount and for a time sufficient to increase the levels of testosterone.
- Defendant had actual, first-hand knowledge of the '908 patent after the June 19, 2012 issuance of the patent, the day of which a very publicly available and widely known press release was issued by Plaintiff announcing the issuance of the patent. The press release stated as follows:

"ThermoLife International, LLC (ThermoLife) announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,202,908 (the '908 patent) for ThermoLife's novel use of D-Aspartic acid (DAA). The patented method uses a DAA compound to increase the levels of testosterone, growth hormone, and/or insulin-like growth factor 1 in adult males. The potential benefits of DAA are astounding and the patented method will transform testosterone boosting dietary supplements and methods.

ThermoLife has a long history of developing innovative and proven products and processes. With the addition of the '908 patent, ThermoLife has been awarded seven patents covering more than 20 various compounds and methods of use, and still has many pending applications in the pipeline and new technologies at various stages of development.

These patents protect ThermoLife's innovative and proven products and methods, as well as validate ThermoLife's market leadership in new dietary ingredient research. These patents also allow ThermoLife to continue building confidence with its licensing partners and give consumers and companies that work with ThermoLife assurance that they are buying one-of-a-kind products that they cannot get elsewhere.

About Thermolife

Founded in 1998, ThermoLife is dedicated to developing real products and methods that work. ThermoLife is a leading manufacturer in the sports nutrition and supplement industry. ThermoLife is committed to developing only the purest, most effective, and innovative products. For more information about ThermoLife and its patents, or to license any of ThermoLife's patented ingredients contact Ron Kramer at Ron(at)ThermoLife(dot)com."

- 32. Thereafter, Plaintiff sent detailed communications to Defendant to notify Defendant of the patent prior to the filing of this suit.
- 33. Defendant has brazenly and willfully decided to infringe the '908 patent despite knowledge of the patent's existence and each of their infringements of the patent.

28 || / / /

14 15

16 17

18

19

20

21 22

23 24

25 26

27 28

- 34. At a minimum, and in the alternative, Plaintiff pleads that Defendant willfully blinded itself to the infringing nature of the accused products' sales.
- Defendant has not ceased its own direct infringements, contributory 35. infringements, or inducements of infringements by end-users despite their clear knowledge of the '908 patent.
- In sum, Defendant specifically induces end-users to use the accused 36. products, and particularly the d-aspartic acid compound in these products, for increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the d-aspartic acid compound present in the products in an amount and for a time sufficient to increase the levels of testosterone, which is the very method described in the '908 patent.
- This method is the sole reason Defendant includes the d-aspartic acid 37. compound in their products, and end-users' experiences are consistent with the fact that they have practiced the method, in that end-users have increased their levels of testosterone by ingesting the d-aspartic acid compound present in the accused products.
- Defendant's infringing activities have not stopped despite its knowledge of 38. the patent's existence.

V. FIRST CAUSE OF ACTION

Infringement of U.S. Patent No. 8,202,908

- 39. Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs of this Complaint as if fully set forth herein.
- The Defendant has in the past and still is literally infringing or infringing 40. under the doctrine of equivalents, directly and indirectly through contributory and/or induced infringement, claims 1 and 2 of the '908 patent by making, using, selling, and offering for sale dietary supplements embodying claims 1 and 2 of the patented invention, and will continue to do so unless enjoined by this Court.
- Examples of Defendant's direct infringement include, without limitation, 41. the fact that Defendant's employees, agents, representatives and other persons

24 25

26

22

23

27 28

sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities, have taken, used, and orally administered the accused products which have the effect, without limitation, of increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the D-aspartic acid compound present in the products in an amount and for a time sufficient to increase the levels of testosterone, and when administered pursuant to the accused products' instructions for use, leading to an ingestion of about 1 to 20 grams of the D-aspartic acid compound daily.

- 42. Defendant has encouraged and is aware of these persons' oral administration of the accused for these purposes, these persons are acting under Defendant's direction and control, and therefore Defendant is directly practicing the method set forth in the '908 patent.
- 43. End-users of the accused products are also direct infringers of the '908 patent, because they have taken, used, and orally ingested the accused products which have the effect, without limitation, of increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the D-aspartic acid compound present in the products in an amount and for a time sufficient to increase the levels of testosterone, and when administered pursuant to the accused products' instructions for use, leading to an ingestion of between about 1 to 20 grams of the D-aspartic acid compound daily.
- Therefore, these end-users practice the method as set forth in the '908 44. patent and directly infringe the patent.
- Defendant's labels and advertising explain the elements or essential 45. elements of the method disclosed in the '908 patent to end-users and encourage, urge, and induce the products' end-users to purchase and orally administer the accused products to practice that method.
- 46. The accused products are not suitable for non-infringing uses, and none of Defendant's labels or advertisements for the products disclose any uses for the D-

3

8

9

7

6

10 11

12 13

14 15

17 18

16

19

20 21

22 23

24

25 26

27 28 aspartic acid compound in the products that do not infringe upon the method disclosed in the '908 patent.

- 47. Defendant has knowledge that the accused products are especially adapted by end-users of the products for increasing the levels of testosterone in adult male humans taking the accused products, by having them orally ingest the D-aspartic acid compound present in the products in an amount and for a time sufficient to increase the levels of testosterone.
- 48. Defendant encourages, urges, and induces the accused products' end-users to purchase and orally administer the products to increase the levels of testosterone in adult male humans taking the products, by having them orally ingest the D-aspartic acid compound present in the products in an amount and for a time sufficient to increase the levels of testosterone – and Defendant has done so in the past.
- 49. Defendant therefore is liable for contributory infringement of claims 1 and 2 of the '908 patent.
- 50. Defendant has intentionally and knowingly induced, encouraged, and urged end-users of the accused products to purchase and orally administer the products for the purpose, without limitation, of increasing the levels of testosterone in adult male humans taking the products, by having them orally ingest the D-aspartic acid compound present in the products in an amount and for a time sufficient to increase the levels of testosterone, and instructing them to do so in a daily amount of between about 1 and 20 grams of the compound daily.
- 51. Defendant has actual, first-hand knowledge of the '908 patent, but has not ceased their contributory infringement or inducement of infringements by end-users despite their knowledge of the '908 patent.
- 52. Defendant is therefore liable for induced infringement of claims 1 and 2 of the '908 patent.
- 53. Defendant's activities have been without express or implied license by Plaintiff.

- 54. The infringements by Defendant have been and continue to be willful, since the infringements have not ceased.
- 55. As a result of Defendant's acts of infringement, Plaintiff has suffered and will continue to suffer damages in an amount to be proved at trial.
- 56. As a result of Defendant's acts of infringement, Plaintiff has been and will continue to be irreparably harmed by Defendant's infringements and inducements, which will continue unless Defendant is enjoined by this Court.
- 57. Plaintiff believes that Defendant's past infringements and/or continuing infringements have been deliberate and willful, and that this case is therefore an exceptional case, which warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285.

VI. PRAYER FOR RELIEF

WHEREFORE, Plaintiff prays for entry of judgment against Defendant as follows:

- 1. A declaration that Defendant has infringed the '908 patent under 35 U.S.C. §§ 271 et seq.;
- 3. That injunctions, preliminary and permanent, be issued by this Court restraining Defendant, its respective officers, agents, servants, directors, and employees, and all persons in active concert or participation with each, from directly or indirectly infringing, or inducing or contributing to the infringement by others of, the '908 patent;
- 4. That Defendant be required to provide to Plaintiff an accounting of all gains, profits, and advantages derived by Defendant's infringement of the '908 patent, and that Plaintiff be awarded damages adequate to compensate Plaintiff for the wrongful infringing acts by Defendant, in accordance with 35 U.S.C. § 284;
- 5. That the damages awarded to Plaintiff with regard to the '908 patent be increased up to three times, in view of Defendant's willful infringement, in accordance with 35 U.S.C. § 284;

6. That this case be declared to be exceptional in favor of Plaintiff under 35 1 U.S.C. § 285, and that Plaintiff be awarded its reasonable attorneys' fees and other 2 expenses incurred in connection with this action; 3 7. That Plaintiff be awarded its interest and costs of suit incurred in this 4 action; 5 8. Compensatory damages; 6 9. Punitive damages; and 7 That Plaintiff be awarded such other and further relief as this Court may 10. 8 deem just and proper. 9 10 Respectfully submitted, NEWPORT TRIAL GROUP 11 A Professional Corporation 12 Dated: February 20, 2013 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

DEMAND FOR JURY TRIAL Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiff hereby demands a jury trial for all issues in this case that properly are subject to a jury trial. Respectfully submitted, NEWPORT TRIAL GROUP A Professional Corporation Dated: February 20, 2013 By: Attorneys for Plaintiff

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA

NOTICE OF ASSIGNMENT TO UNITED STATES MAGISTRATE JUDGE FOR DISCOVERY

This case has been assigned to District Judge Dale S. Fischer and the assigned discovery Magistrate Judge is Jean P. Rosenbluth.

The case number on all documents filed with the Court should read as follows:

CV13- 1274 DSF (JPRx)

Pursuant to General Order 05-07 of the United States District Court for the Central District of California, the Magistrate Judge has been designated to hear discovery related motions.

All discovery related motions should be noticed on the calendar of the Magistrate Judge

NOTICE TO COUNSEL

A copy of this notice must be served with the summons and complaint on all defendants (if a removal action is filed, a copy of this notice must be served on all plaintiffs).

Subsequent documents must be filed at the following location:

M	Western Division									
	312 N. Spring St., Rm. G									
	Los Angeles, CA 90012									

Southern Division
411 West Fourth St., Rm. 1-053
Santa Ana, CA 92701-4516

Eastern Division 3470 Twelfth St., Rm. 134 Riverside, CA 92501

Failure to file at the proper location will result in your documents being returned to you.

Name & Address: NEWPORT TRIAL GROUP Tyler J. Woods (State Bar No. 232464) Richard H. Hikida (State Bar No. 196149) Scott J. Ferrell (State Bar No. 202091) 895 Dove Street, Ste 425, Newport Beach, CA 92660 UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA THERMOLIFE INTERNATIONAL LLC CASE NUMBER CV13-01274 DSF (JPRx) PLAINTIFF(S) V. GNC CORPORATION GENERAL NUTRITION CENTERS, INC.; and GENERAL NUTRITION CORPORATION **SUMMONS** DEFENDANT(S). TO: DEFENDANT(S): A lawsuit has been filed against you. Within 21 days after service of this summons on you (not counting the day you received it), you must serve on the plaintiff an answer to the attached of complaint amended complaint □ counterclaim □ cross-claim or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff's attorney. Newport Trial Group . whose address is 895 Dove Street, Suite 425, Newport Beach, CA 92660 . If you fail to do so, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court. Clerk, U.S. District Court Dated: (Seal of the Co [Use 60 days if the defendant is the United States or a United States agency, or is an officer or employee of the United States. Allowed 60 days by Rule 12(a)(3)]. CV-01A (10/11 SUMMONS

Name & Address: NEWPORT TRIAL GROUP Tyler J. Woods (State Bar No. 232464) Richard H. Hikida (State Bar No. 196149) Scott J. Ferrell (State Bar No. 202091) 895 Dove Street, Ste 425, Newport Beach, CA 92660 UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA THERMOLIFE INTERNATIONAL LLC CASE NUMBER CV13-01274 DSF (JPRx) PLAINTIFF(S) V. GNC CORPORATION GENERAL NUTRITION CENTERS, INC.; and GENERAL NUTRITION CORPORATION **SUMMONS** DEFENDANT(S). TO: DEFENDANT(S): A lawsuit has been filed against you. Within __21 __days after service of this summons on you (not counting the day you received it), you must serve on the plaintiff an answer to the attached ♥ complaint □ amended complaint □ counterclaim □ cross-claim or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff's attorney, Newport Trial Group , whose address is 895 Dove Street, Suite 425, Newport Beach, CA 92660 . If you fail to do so, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court. Clerk, U.S. District Court & Dated: FEB 2 1 2013 (Seal of the Court) [Use 60 days if the defendant is the United States or a United States agency, or is an officer or employee of the United States. Allowed 60 days by Rule 12(a)(3)]. CV-01A (10/11 SUMMONS

UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA CIVIL COVER SHEET

I (a) PLAINTIFFS (Check be THERMOLIFE INTERI	(DEFENDANTS GNC CORPORATION; GENERAL NUTRITION CENTERS, INC.; and GENERAL NUTRITION CORPROATION								
(b) Attorneys (Firm Name, A yourself, provide same.) NEWPORT TRIAL GRO	Ĭ	orneys (If Knov	wn)							
92660 Tel; (949) 706-6464 Fi	ax (949)706-6469		Ì							
II. BASIS OF JURISDICTIO	N (Place an X in one box only.)	III.	CITIZENSHIE (Place an X in o	OF PRINCIPONE box for plain	PAL PART	IES - I	For Diversity Case efendant.)	s Only	·····	
☐ 1 U.S. Government Plaintiff	☐ 3 Federal Question (U.S. Government Not a Party	() Citiz	en of This State		PTF □ 1	DEF	Incorporated or of Business in the		PTF □ 4	DEF □ 4
☐ 2 U.S. Government Defendar	☐ 2 U.S. Government Defendant			tate	□2	□2		I Principal Place	d 5	5 5
		Citiz	en or Subject of	a Foreign Cou	ntry □3	□3	Foreign Nation		□6	□6
IV. ORIGIN (Place an X in one box only.) 1 Original Proceeding State Court Appellate Court Appellate Court Appellate Court Proceeding State Court Appellate C										
CLASS ACTION under F.R.O		163 (170 (1		EY DEMANI			mrr. e TRD			
VI. CAUSE OF ACTION (Cit	e the U.S. Civil Statute under whi	ch you are fil						atutes unless dive	rsity.)	
28 U.S.C. §§ 1331, 1338, a VII. NATURE OF SUIT (Plac										
OTHER STATUTES	CONTRACT	ananasana d	RTS	TORT	MEGO (OTAK SAMA)	USON DEGROOMS	PRISONER	LAB	The Market State	Aug American
□ 490 Cable/Sat TV □ 810 Selective Service □ 850 Securities/Commodities/ Exchange □ 875 Customer Challenge 12 USC 3410	□ 110 Insurance □ 120 Marine □ 130 Miller Act □ 140 Negotiable Instrument □ 150 Recovery of ○ Overpayment & □ Enforcement of □ Judgment □ 151 Medicare Act □ 152 Recovery of Defaulted Student Loan (Excl. Veterans) □ 153 Recovery of ○ Overpayment of Veteran's Benefits □ 160 Stockholders' Suits □ 190 Other Contract □ 195 Contract Product □ Liability □ 196 Franchise □ REAL PROPERTY □ 210 Land Condemnation □ 220 Foreclosure □ 230 Rent Lease & Ejectment □ 240 Torts to Land □ 245 Tort Product Liability □ 290 All Other Real Property	□ 310 Airp □ 315 Airp □ 315 Airp □ 1315 Airp □ 315 Airp □ 330 Fed. □ 340 Mari □ 345 Mari □ 345 Moto □ 355 Moto □ 360 Othe □ Injur □ 362 Perso □ 368 Perso □ 786 Perso □ 1368 Asbe □ 368 Asbe	lane Product dity ult, Libel & der Employers' dity ne ne Product dity or Vehicle or Vehicle or Liability r Personal y onal Injury- Malpractice onal Injury- ict Liability stos Personal y Product lity RATION alization ication as Corpus- Detaince	☐ 385 Property	Fraud In Lending Personal Ity Damage Ity Damage Ity Damage It Liability PTCY 28 USC awal 28 57 IHTS ment g/Accotions an with ities - ment an with ities -	□ 510 □ 530 □ 535 □ 540 □ 555 □ 555 □ 610 □ 620 □ 625 □ 630 □ 640 □ 650 □ 660	Other Civil Rights Prison Condition RFEITURE / PENALTY Agriculture Other Food & Drug Drug Related Seizure of Property 21 USC 881 Liquor Laws R.R. & Truck Airline Regs Occupational Safety /Health	□ 710 Fair Lab	Igmt. s s (gmt. s g gmt. g & gmt. g & gmt. Labor n et. Inc. Act RIGH atts rk EURIT (g) UWW (g) LAX SU LAX SU d Party d Party	Act TS Y 3)
	CASE Number:CV1		DSF (JPI	·····			 -			

CV-71 (05/08)

VIII(a). IDENTICAL CASES: Has If yes, list case number(s):	s this action been pr	eviously filed in this court ar	nd dismissed, remanded or closed? ▼No □ Yes				
VIII(b). RELATED CASES: Have If yes, list case number(s):	e any cases been pre	eviously filed in this court the	at are related to the present case? ☑ No □ Yes				
□ C.	Arise from the same Call for determinati For other reasons w	e or closely related transaction on of the same or substantial ould entail substantial duplic	ons, happenings, or events; or Ily related or similar questions of law and fact; or cation of labor if heard by different judges; or c, and one of the factors identified above in a, b or c also is present.				
IX. VENUE: (When completing the			• •				
			if other than California; or Foreign Country, in which EACH named plaintiff resides. This box is checked, go to item (b).				
County in this District:*			California County outside of this District; State, if other than California; or Foreign Country				
			THERMOLIFE INTERNATIONAL, LLC - Maricopa County, Arizona				
(b) List the County in this District; Check here if the government, it	California County o s agencies or emplo	utside of this District; State i	if other than California; or Foreign Country, in which EACH named defendant resides. If this box is checked, go to item (c).				
County in this District:*			California County outside of this District; State, if other than California; or Foreign Country				
			GNC CORPORATION; GENERAL NUTRITION CENTERS, INC.; and GENERAL NUTRITION CORPORATION - Allegheny County, Pennsylvania				
(c) List the County in this District; (if other than California; or Foreign Country, in which EACH claim arose.				
County in this District:*			California County outside of this District; State, if other than California; or Foreign Country				
Plaintiff's Claim - Los Angeles, (CA						
* Los Angeles, Orange, San Bernar Note: In land condemnation cases, us	dino, Riverside, Vo	entura, Santa Barbara, or S tract of land involved	San Luis Obispo Counties				
X. SIGNATURE OF ATTORNEY (OR PRO PER):	\/U1.	Date February 20, 2013				
or other papers as required by law	 This form, approv 	ed by the Judicial Conference	rmation contained herein neither replace nor supplement the filing and service of pleadings to of the United States in September 1974, is required pursuant to Local Rule 3-1 is not filed ting the civil docket sheet. (For more detailed instructions, see separate instructions sheet.)				
Key to Statistical codes relating to So	cial Security Cases:						
Nature of Suit Code	Abbreviation	Substantive Statement of	f Cause of Action				
861	НІА	All claims for health insurance benefits (Medicare) under Title 18, Part A, of the Social Security Act, as amended. Also, include claims by hospitals, skilled nursing facilities, etc., for certification as providers of services under the program. (42 U.S.C. 1935FF(b))					
862	BL	All claims for "Black Lung" benefits under Title 4, Part B, of the Federal Coal Mine Health and Safety Act of 1969. (30 U.S.C. 923)					
863	DIWC	All claims filed by insured workers for disability insurance benefits under Title 2 of the Social Security Act, as amended; plus all claims filed for child's insurance benefits based on disability. (42 U.S.C. 405(g))					
863	DIWW	All claims filed for widows or widowers insurance benefits based on disability under Title 2 of the Social Security Act, as amended. (42 U.S.C. 405(g))					
864	SSID	All claims for supplemental security income payments based upon disability filed under Title 16 of the Social Security Act, as amended.					
865	RSI	All claims for retirement (old age) and survivors benefits under Title 2 of the Social Security Act, as amended. (42 U.S.C. (g))					

CV-71 (05/08) CIVIL COVER SHEET Page 2 of 2